Categories
Uncategorized

Johnson & Johnson starts trial of COVID-19 vaccine after producing immune response in primates – MarketWatch

Johnson & Johnson JNJ, -0.19% said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine…

Johnson & Johnson
JNJ,
-0.19%
said Thursday that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The vaccine…
Read More

Please follow and like us:

Leave a Reply

Your email address will not be published. Required fields are marked *